A histone deacetylase inhibitor, azelaic bishydroxamic acid, shows cytotoxicity on Epstein-Barr virus transformed B-cell lines: a potential therapy for posttransplant lymphoproliferative disease.

Source:http://linkedlifedata.com/resource/pubmed/id/11821743

Transplantation 2002 Jan 27 73 2 271-9

Download in:

View as

Triples

General Info

PMID
11821743